Zheng et al. constructed honokiol (HNK), which can inhibit PIK3/mTOR (mammalian target of rapamycin), and the antitumor agent disulfiram/copper (DSF/Cu) into exosomes (CDX-LIPO) and targeted tumor capillary-specific Nicotinic acetylcholine receptors via DCDX. Here, MTOR is linked to neoplasm.